Liver transplantation: Impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival

Investigative Radiology

Volumn 47, Issue 6, 2012, Pages 353-358

  Wibmer, Andreas ^a   Aliya, Qayyum ^b   Steininger, Rudolf ^a   Trauner, Michael ^a   Maresch, Judith ^a   Mühlbacher, Ferdinand ^a   Ba Ssalamah, Ahmed ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gd EOB DTPA; liver transplantation; magnetic resonance imaging

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLINESTERASE; GADOXETIC ACID;

ADULT; ALCOHOL INDUCED LIVER CIRRHOSIS; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; B CELL LYMPHOMA; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILE DUCT STONE; BILIARY EXCRETION; BILIRUBIN BLOOD LEVEL; CHOLANGIOLITHIASIS; CHOLINESTERASE BLOOD LEVEL; COMMON BILE DUCT; CONTRAST ENHANCEMENT; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETRANSPLANTATION; RETRANSPLANTATION FREE SURVIVAL; RETROSPECTIVE STUDY;

EID: 84861097447     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e318245f7be     Document Type: Article

References (31)

1. Berg CL, Steffick DE, Edwards EB, et al. Liver and intestine transplantation in the United States 1998-2007. Am J Transplant. 2009;9(4 pt 2):907-931.
2. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9:1231-1243.
3. Starzl TE, Marchioro TL, Vonkaulla KN, et al. Homotransplantation of the liver in humans. Surg Gynecol Obstet. 1963;117:659-676.
4. Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver. Ann Surg. 1968;168:392-415.
5. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet. 1979;2:1033-1036.
6. Starzl TE, Todo S, Fung J, et al. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000-1004.
7. Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology. 2010;51: 1869-1884.
8. van der Hilst CS, Ijtsma AJ, Slooff MJ, et al. Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries. Med Care Res Rev. 2009;66:3-22.
9. Hendriks HG, van der Meer J, de Wolf JT, et al. Intraoperative blood transfusion requirement is the main determinant of early surgical re-intervention after orthotopic liver transplantation. Transpl Int. 2005;17:673-679.
10. Lock J, Reinhold T, Bloch A, et al. The cost of graft failure and other severe complications after liver transplantationVexperience from a German Transplant Center. Ann Transplant. 2010;15:11-18.
11. Kim BS, Kim TK, Jung DJ, et al. Vascular complications after living related liver transplantation: evaluation with gadolinium-enhanced three-dimensional MR angiography. AJR Am J Roentgenol. 2003;181:467-474.
12. Pecchi A, De Santis M, Di Benedetto F, et al. Role of magnetic resonance cholangiography in biliary complications of orthotopic liver transplantation. Radiol Med. 2010;115:1065-1079.
13. Singh AK, Nachiappan AC, Verma HA, et al. Postoperative imaging in liver transplantation: what radiologists should know. Radiographics. 2010;30: 339-351.
14. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOBDTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
15. Gschwend S, Ebert W, Schultze-Mosgau M, et al. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol. 2011;46:556-566.
16. Zech CJ, Vos B, Nordell A, et al. Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol. 2009;44:305-310.
17. Lee NK, Kim S, Lee JW, et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics. 2009;29:1707-1724.
18. Shimada K, Isoda H, Hirokawa Y, et al. Comparison of gadolinium-EOBDTPA- enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol. 2010;20:2690-2698.
19. Seo HJ, Kim MJ, Lee JD, et al. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol. 2011;46:548-555.
20. Motosugi U, Ichikawa T, Sano K, et al. Double-dose gadoxetic acidYenhanced magnetic resonance imaging in patients with chronic liver disease. Invest Radiol. 2011;46:141-145.
21. Nilsson H, Blomqvist L, Douglas L, et al. Assessment of liver function in primary biliary cirrhosis using Gd-EOB-DTPA-enhanced liver MRI. HPB (Oxford). 2010;12:567-576.
22. Tajima T, Takao H, Akai H, et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34:362-366.
23. Ni Y, Marchal G, Lukito G, et al. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. Radiology. 1994;190:753-758.
24. Muhler A, Clement O, Saeed M, et al. Gadolinium-ethoxybenzyl-DTPA, a new liver-directed magnetic resonance contrast agent. Absence of acute hepatotoxic, cardiovascular, or immunogenic effects. Invest Radiol. 1993;28:26-32.
25. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd- EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199: 177-183.
26. Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997;7:683-688.
27. Shimizu J, Dono K, Gotoh M, et al. Evaluation of regional liver function by gadolinium-EOB-DTPA-enhanced MR imaging. Dig Dis Sci. 1999;44: 1330-1337.
28. Takao H, Akai H, Tajima T, et al. MR imaging of the biliary tract with Gd-EOBDTPA: effect of liver function on signal intensity. Eur J Radiol. 2011;77: 325-329.
29. Tschirch FT, Struwe A, Petrowsky H, et al. Contrast-enhanced MR cholangiography with Gd-EOB-DTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol. 2008;18:1577-1586.
30. Katsube T, Okada M, Kumano S, et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest Radiol. 2011;46:277-283.
31. Tamada T, Ito K, Higaki A, et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80:e11Ye16.